{"entity":{"type":"insider","cik":"0001733204","url":"/insider/0001733204","json_url":"/insider/0001733204.json","name":"Spellman David A","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":7,"n_filings":5,"first":"2021-04-01","last":"2023-05-18","span_basis":"filed_date"},"name_variants":[{"name":"Spellman David A","source":"filing","n_filings":5,"first_seen":"2021-04-01","last_seen":"2023-05-18"}],"transactions":[{"id":7933711,"accession":"0001562180-23-004253","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-23-004253","line_url":"/filing/0001562180-23-004253#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001733204","owner_name":"Spellman David A","owner_display_name":"Spellman David A","owner_url":"/insider/0001733204","role":"Officer (SVP, CFO and Treasurer)","role_mark":"O","role_mark_label":"Officer (SVP, CFO and Treasurer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CFO and Treasurer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":63567.0,"shares_display":"63,567","price_per_share":1.068,"price_display":"1.07","price_state":"stated","total_value":67889.556,"total_display":"67,889.56","total_whole":"67,890","shares_owned_after":446483.0,"shares_owned_after_display":"446,483","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-16","filed_date":"2023-05-18","scope":"insider"},{"id":8083792,"accession":"0001562180-23-002197","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-23-002197","line_url":"/filing/0001562180-23-002197","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001733204","owner_name":"Spellman David A","owner_display_name":"Spellman David A","owner_url":"/insider/0001733204","role":"Officer (SVP, CFO and Treasurer)","role_mark":"O","role_mark_label":"Officer (SVP, CFO and Treasurer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CFO and Treasurer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7210.0,"shares_display":"7,210","price_per_share":0.8775,"price_display":"0.88","price_state":"stated","total_value":6326.775,"total_display":"6,326.78","total_whole":"6,327","shares_owned_after":510860.0,"shares_owned_after_display":"510,860","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-01","filed_date":"2023-03-03","scope":"insider","n_lines":2},{"id":8266210,"accession":"0001562180-23-002038","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-23-002038","line_url":"/filing/0001562180-23-002038#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001733204","owner_name":"Spellman David A","owner_display_name":"Spellman David A","owner_url":"/insider/0001733204","role":"Officer (SVP, CFO and Treasurer)","role_mark":"O","role_mark_label":"Officer (SVP, CFO and Treasurer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CFO and Treasurer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7539.0,"shares_display":"7,539","price_per_share":0.8132,"price_display":"0.81","price_state":"stated","total_value":6130.7148,"total_display":"6,130.71","total_whole":"6,131","shares_owned_after":517260.0,"shares_owned_after_display":"517,260","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-27","filed_date":"2023-03-01","scope":"insider"},{"id":6495334,"accession":"0001562180-22-002160","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001562180-22-002160","line_url":"/filing/0001562180-22-002160#line-3","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001733204","owner_name":"Spellman David A","owner_display_name":"Spellman David A","owner_url":"/insider/0001733204","role":"Officer (SVP, CFO and Treasurer)","role_mark":"O","role_mark_label":"Officer (SVP, CFO and Treasurer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CFO and Treasurer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":803.0,"shares_display":"803","price_per_share":2.1707,"price_display":"2.17","price_state":"stated","total_value":1743.0721,"total_display":"1,743.07","total_whole":"1,743","shares_owned_after":128599.0,"shares_owned_after_display":"128,599","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-01","filed_date":"2022-03-02","scope":"insider"},{"id":6495332,"accession":"0001562180-22-002160","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-22-002160","line_url":"/filing/0001562180-22-002160#line-2","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001733204","owner_name":"Spellman David A","owner_display_name":"Spellman David A","owner_url":"/insider/0001733204","role":"Officer (SVP, CFO and Treasurer)","role_mark":"O","role_mark_label":"Officer (SVP, CFO and Treasurer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CFO and Treasurer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7400.0,"shares_display":"7,400","price_per_share":2.1548,"price_display":"2.15","price_state":"stated","total_value":15945.52,"total_display":"15,945.52","total_whole":"15,946","shares_owned_after":69402.0,"shares_owned_after_display":"69,402","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-28","filed_date":"2022-03-02","scope":"insider"},{"id":4697695,"accession":"0001562180-21-002543","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-21-002543","line_url":"/filing/0001562180-21-002543#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001733204","owner_name":"Spellman David A","owner_display_name":"Spellman David A","owner_url":"/insider/0001733204","role":"Officer (SVP, CFO and Treasurer)","role_mark":"O","role_mark_label":"Officer (SVP, CFO and Treasurer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CFO and Treasurer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":790.0,"shares_display":"790","price_per_share":3.4,"price_display":"3.40","price_state":"stated","total_value":2686.0,"total_display":"2,686.00","total_whole":"2,686","shares_owned_after":76802.0,"shares_owned_after_display":"76,802","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-01","filed_date":"2021-04-01","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":7,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":7,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":7},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001517022","name":"Akebia Therapeutics, Inc.","url":"/issuer/0001517022","role":"Officer (SVP, CFO and Treasurer)","n_filings":5,"first_seen":"2021-04-01","last_seen":"2023-05-18"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001733204","retrieved_at":"2026-08-25T08:07:44+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}